YouSaid · the spoken record

Leah

lines on the record: 24
first: 2021-07-20
most recent: 2021-07-20
sittings or episodes: 1
sources: podcast

Every line below is reproduced as it was said and linked to the record it came from. Nothing here is summarised or generated. Directory · Search · Corrections

“Solid technology coming into healthcare. I think in the past you have seen fax machines and sort of like matrix printers and all sorts still in hospitals, bringing AI sort of the most modern piece of software technology, I think, is very much approaching now. I think us here on this call and a couple other players can absolutely lead the charge on this. From our side, what it means is really making diagnosis of cancer really reliable and absolutely making cancer a less feared disease for sure. As a side effect, I very much hope that we can break down the barriers, evolves, and really lead the innovation to everyone what it looks like, how to bring safe AI into everyday practice.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“See that Veer in a very exciting time point where I think COVID has taught us that bringing tech into healthcare is actually a really good idea and doable. It's actually coinciding with AI getting mature enough. And I think the analysis of healthcare AI and the evaluation of healthcare AI is also getting mature enough. I think that's a very good sort of crossroads. And so basically, I think this can be a starting point for us seeing.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“I mean, for us, we are a deeply mission driven organization and we are in the space because we want to make a difference for women. And I think our future will be guided by that. We want to continue empowering women with the tools that we have and those tools being massive in large data sets and medical wearable and a good understanding of AI and algorithms. And with that, we want to build continuously. We want to build applications that will make women's lives better and easier and healthier. And as I mentioned before, we are looking at the contraceptive space. We are looking at the pregnancy space. We're looking at the menopause space. That's really where we want to make a difference. And there's still quite a bit to do there. So I'm not going to venture further than that. But we really hope that we can bring more products to market.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“So next stage, as I said, for asset flow is really being able to reach the wider total addressable market and also looking at how we can evolve, for example, the other half of the world in the journey, because if you think about everything with female health, it's historically been a taboo subject. It's seen as being a female thing. And if we look at our strongest performing segments in the user engagement that is trying to conceive, becoming a mom to be, becoming a real mom, there's a real appetite and really amazing stories from our users, from the partners in how they engage with the content, how they want to be part of the conversation, and how do we really make it a joint experience as opposed to them and us situation.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“I think one of the biggest barriers is when someone does something really, really large scale and long-term, like really, which is just fundamentally the case in LeapTact, it's actually really hard to find the growth capital for and generally the capital to fund that. I believe that has been one of the concerns in the past. I think that's probably less so the issue currently, which is great. And I think now with the advent and with sort of like the clinical evidence that's coming to AI by some of the key players, I think we're getting actually the demand. Where now it's getting the gross capital to fund the extent of the need that is coming to us is going to be the next vapor complexity. These are high quality problems though, I think, at this stage, which is very welcome, I think.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Chiron, very much focusing on cancer as a whole. We're going through different sub cancer types. We believe we have very much solved almost all the problems or cancer of almost all the problems in breast cancer screening. We have some of the largest studies. And many people don't know this is one of the hardest problems to the point that actually two radiologists have to look at every single scan. Normally it's one almost everywhere else. This is the one where it needs to. So it's one of the hardest problems. Working off of that, we believe that we can expand quite a bit further to the other cancer areas and we have early successes on that. And so that's the extremely exciting future, I think, looking forward. We're really aiming to make cancer much less of a scary disease than previously has been. That's for all anatomical parts, for all genders longer term, but very much, I think, off of the platform of breast cancer screening. I would say on the topic of what are the”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Yes, I would 100% echo what was just said. So health, if we think about health, Femtech, menstrual health in particular, it isn't the sexiest topic. Femtech is still perceived to be niche, not only by investment markets, but also the total addressable market, which is by definition half the world's population on the planet directly and the other half indirectly. So people feel more inclined to look into tracking apps or tracking hardware products only if they feel they have a medical or health problem. They're not thinking about the benefits of tracking their cycle or female well-being for everyday well-being, feeling empowered, better understanding how to biohack these cycles because they haven't had the first-hand experience. So at Flow in app, we're seeing that once they break through the barrier and they download the app, the user value is immediately visible through retention and repeat subscriptions. So for us, we're really focused on spreading awareness and education of the cycle.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Running into this and basically detecting COVID for women every single month because they didn't understand the baseline so they just assumed every time temperature goes up they probably have COVID and that is not the case. There's a natural fluctuation that comes because of hormonal changes and understanding this baseline physiology as we do in detail allows us now to build other medical applications on top of that for women where we use the physiology and the insights that we have. So it's an example that really points towards the fact that having this broad database now allows us to really use wearables for any kind of medical application. Eva wants to really stay in the women's health field. We worked on COVID because it was, as you all know, a pressing issue, but it just points to the fact that there's so much we can still do with the technology.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, so I mentioned before that Ava is really looking into other areas of women's health. You have to imagine that right now we're probably sitting on the broadest data set of physiological data of women related to the menstrual cycle. So there's a TOM that we can still do there and can build up. But there's one example that I want to point to, which I think just shows us how the application of wearables and the AI works overall. At the beginning of the COVID pandemic, we started to use our device to try to understand an early detection of COVID. And we've actually started building an algorithm. We are now in a large-scale trial with 20,000 people in the Netherlands to validate our algorithm to early detect COVID. And, you know, one of the interesting things when you build something like that is in order to build a COVID detection, you need to really well understand the baseline of physiology. And the baseline of physiology is really, really complex for women. So what we've seen is we've seen other wearables.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Beyond Femtech, I think it is fair to say that today we have yet to see that, even though the expectation is that it will come. Is Anne. I'd like to add something. When we talk about lack of investments and the ties turning, the other side of the investment market to look at is obviously returns. In flow health case, we've been able to create a product that provides value to the ultimate user that is higher than the monetization point that they're contributing. In the last 12 months, Flow's revenues increased over 107%, and that number of active subscribers is growing kind of forex year and year. So I think there is the question of the investment community, but it's also the question of lack of sizable exits. Where's the monetization model that shows sustainable growth in the industry?”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“User safety medical and scientific soundness and credibility are an absolute must. They're table stakes in the industry. And we rely on sound medical research, original research that we're partnering with world-class universities and in excess of 80 medical advisors to make sure that we achieve safety and scientific soundness of the app. The FDA is against companies seeking approval for pure marketing reasons. And as things currently stand, Flow is not aiming to get regulated under FDA. However, it largely depends on which features we're going to develop moving forward. We absolutely may consider it in the future if we choose to develop the features such as health assistance chatbots that will be able to identify increased risks for certain conditions or anything that provides a diagnostic or medical advice. Or if we aim to move into the fertility contraception space that is also regulated. So I think there is space.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Algorithms, our entire framework is significantly more complex, but then also significantly more accurate. And through that, we're also making more regulated claims, and therefore, we are in a regulated space. And I think for us, this really was in a way a choice, right? So I think different to you, Peter, for us, you can choose to fall on either side of that coin. And we as Ava clearly decided to go the regulatory path. Also, with a look to the future, where we know that. Further applications that we want to build are clearly regulated. And also we have a look to the business model where we said we want to be on the regulated medical track because eventually Want to be paid by payers, which is already the case for us now. We want to sell through providers, which we are also doing.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, I mean, I have a bit of a different viewpoint than Peter, but it's just rooted in the different kind of sub-industries that we're in. If you talk about fertile data tracking, which is still the kind of key product that we have out there, the regulation, I would say, is a lot of gray zone out there. Just to give you an example, if you're an app or you're a wearable, like a Fitbit, you can do cycle tracking for your users and it's not regulated. So you can kind of tell your user, okay, we believe that you're going to ovulate on day 13 and that's not regulated. It's not regulated because the underlying algorithm is really dumb. The only thing that it basically does is it takes cycle length, divides it by two and says, okay, this is your fertile date. And this is how most apps operate. This is how the wearables operate. And that as long as they don't make outrageous claims around that, they can say we're cycle tracking and that's not regulated. The way that Ava has approached this from the very beginning is a different one. We have not one but multiple.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“And what clinical evidence is not needed. AI itself is very much automatic, so it can do clinical trials on a large scale that otherwise are not really have been doable in the past. So we can have volume at our side. We also have an attribute of AI called generalizability that's extremely important to achieve Is pretty much the synonym of patient safety. And I think it's important to shift from traditional regulatory views to sort of regulatory reviews that are necessary for AI. And at Chiron, we very much focused on extremely large-scale clinical trials that are focusing and showing regulators of where the signals are, where the weaknesses are and what to really focus on, what to prove. There's a long way to go, but I think we're making some good headway.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Think in general in healthcare, I think regulation is an extremely important part because I think as patients we all want to be able to believe and trust all the medical processes, devices, drugs, et cetera, that are given to us because otherwise we all would need to be scientists in absolutely every disease. So regulation is really important, I think. However, I do believe the innovation cycle on regulation of regulation itself is not really as fast as it may need to be. And I think also on the front lines we have a bit of a responsibility to push that and show what way we can help regulators understand how to be more efficient and actually what to look for, especially in the field of AI. I think there's quite a bit of nuance and quite a few new areas that we need to push what clinical evidence is really needed.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, so in our specific space, cancer, it's quite easy and clear to see that since cancer is the disease of the genes, and also cancer is very much localized anatomically. But also, as I said, it's very much under stress and peril. Having that tension, I think, to something that finally worked, they can be proud of, I think, in healthcare in general. I think that is extremely important to safeguard. And I think having a category can potentially help. We also very much see ourselves as a healthcare company for sure, but we're very proud that we can focus on breast cancer screening.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Is Anne. To me, Femtech refers to technology, the tech being developed in service of women's health from periods to pregnancy to menopause. So we at Flow Health think that we're firmly in the middle of the Femtech space. The products in the space serve different needs and purposes, including fertility solutions, period tracking, pregnancy, nursing, care, women's sexual wellness, and reproductive system health care. I think the division between medical and lifestyle products in Femtech is somewhat artificial. It's not either or for us. It's both. And for flow specifically, we're aiming to bridge this gap, providing evidence-based, science-backed information and functionality in an engaging way to educate and empower women and everyone who enters to take control of their health.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Are regulated, and all of those things which are typically not the case in the pure tech world. So I think we're still trying to figure out what term works for a company that is working for women, but really in the healthcare space.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“The advantage of being kind of an old startup with our seven years is that we've been actually there when this term was coined. So we remember the space before and after Here's the good things about It's suddenly there were analyst reports on the space. There's this podcast that is around the space, right? So given the space, the name has really helped in terms of attention, also in terms of investor attention. So that has really helped the space. I have to say after a couple of years now, I have this love-hate relationship with the term. And again, I think it's good to give the space a name overall, but we really consider ourselves a healthcare company Putting us on the term of femtech is sometimes putting the wrong label on what we do. We are healthcare. We run clinical trials.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Had Chiron using AI to have diagnosed cancer better. We believe that cancer is primarily a problem in a complicated disease to work with because we don't know enough about it. We don't know even enough about it in general, but primarily we don't know enough about it at the time of diagnosis or even tracking or follow-up. We believe it's very much lending itself to be an AI solvable problem. So we're really using AI to help primarily radiologists diagnosing and tracking cancer well. We're very much focused on breast cancer screening and we're focused on breast cancer screening because that's one of the largest sort of cancer diagnosis problems, the largest scale cancer diagnosis problem across the globe and also probably the most successful screening program across the globe. Many people may not know that it's kind of at peril in most countries.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Fusion that are all changing throughout the menstrual cycle. So, what we're doing now is we're measuring around the million of those data points a night and through different algorithms that allows us to detect the vertical window of women in real time and helps them really optimize their chances of conceiving. And that's how really we started in the fertility world and now we have after a couple of years realized that this technology has tremendous potential also in other spaces within women's health. So we're looking very closely at contraception, at menopause and the pregnancy.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“And what we did is that, okay, good, temperature, we understand that. That should be easier nowadays with wearables, but we also wanted to see if there's other measurements outside of temperature that could be interesting for us to look at. So we started with basically a wearable that just measured everything under the sun that you could possibly measure and had women use it to understand, are there other things that are changing throughout the menstrual cycle than just temperature? And what we came up with is that there's actually multiple things, such as heart rate, hard rate wearability.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Is Leah. So we started AVA around seven years ago, and I have a co-founder, and at that point they were trying to get pregnant. And, you know, if you don't know much about trying to conceive, it sounds very romantic for many couples, but it's also not that easy for some others. And what's really important when you're trying to conceive is that you get your timing right. Women can only really conceive five or six days a cycle. And so it's really important to know when those six days are. And traditionally and over the last decades, that has been done by really kind of cumbersome temperature measurements mostly. So for anyone who hasn't done that in the past, it's really about taking your temperature every single morning at the same time, waking up at that time, even on weekends, and then measuring your temperature. And when it goes up a little bit, that's when you know that you were fertile in the past. And so we looked at that a few years ago and said, okay, this is really kind of ridiculous in a world where we can do everything so easily why it is still so.”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT
“Flow is the world's leading health app for women that supports them during their entire reproductive life cycle from first period When you're in your teens to menopause from pregnancy to young moms. And our vision is to significantly improve the health and well-being of every woman, every girl and person who menstruates in the world. We have over 190 million users, 1.4 million premium subscribers. We support women doing their entire reproductive lives through providing curated cycle and ovulation tracking, personalized health insights, expert tips, and a private community and a safe space for women to share their questions and concerns. I joined Flow coming back from my maternity leave after having had two little babies last year, who are by the way Flow babies. So we use the app to conceive them. So there's a common ground why they are in the world today and why I'm here on this podcast today. And that's flow. I'm incredibly passionate about leveling the playing field for women across the world and the power of technology as an enabler of that. I was doing that previously in my role at Bumble and I'm grateful to be”
2021-07-20 · Goldman Sachs Exchanges · The Future of ‘Femtech’ · IDENTIFIED FROM THE TRANSCRIPT